ACOG

Alpha Cognition Inc. (ACOG) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on the development and sale of treatments for neurodegenerative diseases, primarily Alzheimer's Disease. The company launched its oral tablet formulation, ZUNVEYL, on March 19, 2025. The company is classified as a Non-Accelerated Filer, Smaller Reporting Company, and Emerging Growth Company.

Key Financial Metrics

Note: Q1 2025 comparative figures have been revised due to the reclassification of CAD-denominated options from equity to liability (see Material Changes).

Material Changes vs. Prior Period

• Revenue Mix Shift: Total revenue increased 21% to $3.53M. This was driven by a 910% increase in product sales ($3.50M) following the ZUNVEYL launch, offset by a 99% decrease in licensing revenue ($30k vs. $2.58M) as the one-time upfront payment from the CMSI agreement in the prior year was not repeated.
• Operating Expenses: Total operating expenses rose 84% to $11.63M. Selling, General, and Administrative (SG&A) expenses doubled (101% increase) to $10.26M due to commercial launch costs, increased management fees, and marketing. R&D expenses increased 174% to $1.10M.
• Net Loss Expansion: Net loss widened significantly to $6.48M (vs. $1.73M revised prior year) due to higher operating costs, partially mitigated by a $1.12M non-cash gain from the change in fair value of warrant liabilities.
• Cash Burn: Net cash used in operating activities increased to $11.8M, primarily due to higher employee costs and commercialization expenses.
• Accounting Revision: The company corrected a prior period error regarding the classification of Canadian Dollar (CAD) options. These were reclassified from equity to liabilities, impacting the comparative Q1 2025 net loss and equity balances.

Outlook, Risks, and Unusual Items

• Liquidity: Management states that current cash balances ($54.2M) are sufficient to fund operations for at least the next 12 months. However, the company expects to rely on additional financing (debt, equity, or partnerships) to fully execute commercialization plans.
• Subsequent Events:
  • Royalty Settlement: On April 10, 2026, the company settled all current and future royalty obligations to Galantos Pharma GmbH with a one-time payment of $6,148,318.
  • CAD Option Conversion: On April 30, 2026, the Board approved converting all outstanding CAD-denominated options to USD exercise prices to eliminate currency mismatch risks.
• Internal Controls: The company identified a material weakness in internal controls over financial reporting related to the accounting of warrants, stock options, and deferred taxes. Management is implementing remediation plans, including enhanced month-end reviews and engaging external experts.
• Risks: Key risks include the inability to raise additional capital on acceptable terms, the success of ZUNVEYL commercialization, and the volatility of fair value measurements for warrant liabilities.

Investor Verification Checklist

• Cash Runway: Verify the impact of the $6.15M royalty settlement payment (subsequent event) on the reported $54.2M cash balance and the 12-month liquidity projection.
• Revenue Sustainability: Assess the trajectory of ZUNVEYL product sales versus the one-time nature of the prior year's licensing revenue to understand future revenue stability.
• Internal Control Remediation: Monitor the progress of remediation for the material weakness in financial reporting, specifically regarding the valuation of derivative liabilities.
• Warrant Liability Volatility: Review the sensitivity of the company's net loss to changes in stock price volatility, given the significant non-cash gains/losses recorded from warrant liability revaluations.
• Capital Needs: Evaluate the company's "At-The-Market" (ATM) facility status and potential dilution from future equity raises required to fund commercialization.